Researchers at Harvard Medical School and the University of California, Irvine, have developed a swifter, simpler, cheaper, adaptive technology to generate highly specialized antibodies. They have already used the platform, dubbed AHEAD, to evolve antibodies against the virus that causes COVID-19. Other groups are now investigating those antibodies as the basis for diagnostic tests and therapies.
Harvard Medical School, June 25, 2021
June 25, 2021